ANI Pharmaceuticals (ANIP) Stock Looks Fairly Valued On Current Earnings

ANI Pharmaceuticals has seen its share price move around in recent years, and the stock now changes hands at US$69.62 after a period of weaker returns. The question for anyone looking at ANI Pharmaceuticals today is whether that price can be explained by what the business is earning.

• Over the past 5 years the stock has gained 52.8%, which puts real weight on whether the current earnings profile can support where the share price has ended up.
• Management has announced a recommended cash offer for Egetis Therapeutics that may reshape future earnings, because bringing EMCITATE to the U.S. through ANI’s rare disease platform could affect both growth expectations and the timing of cash flows.
• Your read on ANI Pharmaceuticals is one view; the desks covering it have another. See what analysts think ANI Pharmaceuticals's shares could be worth.

The issue now is whether ANI Pharmaceuticals’ current share price is justified by its earnings when set against the Fair Ratio benchmark.

If you want a broader yardstick for ANI Pharmaceuticals and this Egetis move, compare it with other 42 high quality undervalued stocks as a reference point.

Does ANI Pharmaceuticals Look Fairly Valued on Earnings?

The P/E ratio suits ANI Pharmaceuticals because earnings are a key driver for how investors frame this stock. On current numbers the shares trade on a P/E of about 15.0x, which is slightly below the pharmaceuticals sector average of 15.8x and well under the peer group mark of 34.5x. That positions ANI Pharmaceuticals at a discount to similar businesses that the market prices more highly on this earnings yardstick.

The Fair Ratio benchmark, which reflects what investors might typically pay for a company with ANI Pharmaceuticals’ sector, scale and risk profile, puts the current P/E broadly in line with that tailored reference point. Because the proposed Egetis Therapeutics acquisition adds a potential new rare disease product, the valuation suggests investors are not paying a premium for that plan compared with peers that already carry higher multiples. Explore the numbers behind ANI Pharmaceuticals's P/E valuation.

The ANI Pharmaceuticals Narrative: What Would Justify Today's Price?

Narratives pick up where the Fair Ratio leaves off for ANI Pharmaceuticals, explaining what kind of future growth, profitability and earnings profile would need to occur for the shares to be worth materially more or less than today’s price. All of this is housed on Simply Wall St’s Community page. Each scenario ties a fair value estimate to a specific mix of potential catalysts and key risks so you can track which version of ANI Pharmaceuticals' story is gaining traction over time.

One of the top community narratives on ANI Pharmaceuticals: 34% undervalued

"A key factor is whether Cortrophin Gel and ILUVIEN can convert their large, currently underpenetrated patient pools into sustained prescription volumes..."

Discover why this Narrative puts ANI Pharmaceuticals at 34% undervalued.

One more important check for ANI Pharmaceuticals beyond the earnings multiple

Price ratios only tell you so much about ANI Pharmaceuticals. The character of the people making the decisions, and how their rewards line up with yours, is the missing piece. See who runs ANI Pharmaceuticals and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com